South Africa: US FDA Approves Lilly's Alzheimer's Drug

2 July 2024
Daily Maverick (Johannesburg)
analysis By Reuters

The U.S. Food and Drug Administration on Tuesday gave a green light to Eli Lilly's LLY.N donanemab for patients with early Alzheimer's, making it the second approved drug for slowing the progress of the brain-wasting disease.

The approval for the drug branded Kisunla is in line with the recommendations of the agency's outside experts who unanimously backed the use of the drug in patients with early Alzheimer's disease, saying that the benefits of the drug outweighed its risks.

Lilly has priced Kisunla at $695.65 per vial, which would be $32,000 for a 12-month treatment.

(Reporting By Deena Beasley in Los Angeles and Bhanvi Satija and Mariam Sunny in Bengaluru; Editing by Bill Berkrot and Vijay Kishore)...

Read the full story on Daily Maverick.

Tagged:
Copyright © 2024 Daily Maverick. All rights reserved. Distributed by AllAfrica Global Media (allAfrica.com). To contact the copyright holder directly for corrections — or for permission to republish or make other authorized use of this material, click here.

AllAfrica publishes around 600 reports a day from more than 100 news organizations and over 500 other institutions and individuals, representing a diversity of positions on every topic. We publish news and views ranging from vigorous opponents of governments to government publications and spokespersons. Publishers named above each report are responsible for their own content, which AllAfrica does not have the legal right to edit or correct.

Articles and commentaries that identify allAfrica.com as the publisher are produced or commissioned by AllAfrica. To address comments or complaints, please Contact us.